TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3555164

Group type: COMPARATOR
Intervention: bupivacaine plus 1 ml normal saline (Group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: bupivacaine plus 0.2 mg epinephrine (Group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: bupivacaine plus 0.15 mg clonidine (Group III)
Number of subjects: 60
Study: 30724035

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 123

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 123
Study: 30007057

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg orally 2 hours before surgery and 150 mg at 12 and 24 hours after surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 60
Study: 27511183

Group type: EXPERIMENTAL
Intervention: Dopamine transporter imaging
Number of subjects: 187

Group type: COMPARATOR
Intervention: Follow-up without scan
Number of subjects: 187
Study: 24646327

Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy performed by qualified surgeons
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgeons' laparoscopic and open D2 gastrectomy videos
Number of subjects: 0
Study: 22972030

Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg once daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Prednisolone 7.5 mg once daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Insulin infusion (plasma insulin 200 pmol/l)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Insulin infusion (plasma insulin 600 pmol/l)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 19819661

Group type: EXPERIMENTAL
Intervention: Modified smoking cessation treatment for depressive smokers
Number of subjects: 268

Group type: COMPARATOR
Intervention: Standard smoking cessation treatment
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Modified smoking cessation treatment for higher dependence smokers
Number of subjects: 268
Study: 17211088

Group type: EXPERIMENTAL
Intervention: 1 mg monthly ibandronate
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: 2 mg bi‐monthly ibandronate
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: All ibandronate regimens
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 15911865

Group type: COMPARATOR
Intervention: Cisplatin 50 mg/m(2) every 3 weeks (CPT)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m(2) day 1 plus topotecan 0.75 mg/m(2) days 1 to 3 every 3 weeks (CT)
Number of subjects: 294
Study: 12479047

Group type: EXPERIMENTAL
Intervention: Epristeride 5 mg p.o., twice daily for 120 days
Number of subjects: 141
Study: 10681767

Group type: EXPERIMENTAL
Intervention: Shenmai liquid and improved St. Thomas Crystal Blood (1:4) Cardioplegia (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Improved St. Thomas Crystal Blood (1:4) Cardioplegia (Group A)
Number of subjects: 40
Study: 7622826

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100‐300 mg/day)
Number of subjects: 315
Study: 2533526

Group type: EXPERIMENTAL
Intervention: Nafarelin (200 micrograms twice daily intranasally for 3 or 6 months)
Number of subjects: 15
Study: 6359

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study: 31303080

Group type: EXPERIMENTAL
Intervention: Counseling (four sessions covering medical information about EP, sadness syndrome, mental health improvement, and self-esteem enhancement)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 68
Study: 31078943

Group type: EXPERIMENTAL
Intervention: tRNS applied for 20 min at a current strength of 2 mA during practice blocks
Number of subjects: 34

Group type: COMPARATOR
Intervention: SHAM stimulation during practice blocks
Number of subjects: 34
Study: 28065704

Group type: EXPERIMENTAL
Intervention: Bone-anchored expander
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Tooth-borne maxillary expander (Hyrax)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Untreated (Control)
Number of subjects: 61
Study: 26087654

Group type: EXPERIMENTAL
Intervention: MTX plus adalimumab (ADA)
Number of subjects: 151

Group type: COMPARATOR
Intervention: MTX plus placebo-ADA (PLA)
Number of subjects: 151
Study: 23475016

Group type: EXPERIMENTAL
Intervention: Multimedia-based training
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Practical training
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combination training (multimedia-based training + practical training)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 70
Study: 21690484

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 19

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 19
Study: 19553301

Group type: EXPERIMENTAL
Intervention: 300 g oil-rich fish (salmon) per week (n = 82)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: 300 g lean fish (cod) per week (n = 78)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Dietary advice (DA) (n = 82)
Number of subjects: 242
Study: 17548749

Group type: EXPERIMENTAL
Intervention: Sertraline plus liothyronine
Number of subjects: 124

Group type: COMPARATOR
Intervention: Sertraline plus placebo
Number of subjects: 124
Study: 15485729

Group type: EXPERIMENTAL
Intervention: Prepayment cash incentive of HK dollar 20, n=474
Number of subjects: 949

Group type: COMPARATOR
Intervention: Postpayment cash incentive of HK dollar 20, n=475
Number of subjects: 949
Study: 11584755

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Sulfadoxine + Pyrimethamine (SP)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Resistant infections
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Sensitive infections
Number of subjects: 266
Study: 9591932

Group type: EXPERIMENTAL
Intervention: 10 mg imidapril once per day for 7 days
Number of subjects: 24
Study: 8164861

Group type: EXPERIMENTAL
Intervention: Early ankle mobilization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cast immobilization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 3363169

Group type: EXPERIMENTAL
Intervention: Surgical internal mammary chain dissection and post-operative irradiation
Number of subjects: 1195

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation to the IMC, axilla, chest wall and supraclavicular nodes
Number of subjects: 1195

Group type: COMPARATOR
Intervention: Control group (lateral tumors)
Number of subjects: 1195
Study: 30536920

Group type: EXPERIMENTAL
Intervention: Educational DVD (Gynecology: Beginners Only)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Routine education (Control)
Number of subjects: 57
Study: 28241231

Group type: EXPERIMENTAL
Intervention: Testosterone gel
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 211
Study: 25594526

Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol, programmed to start stimulatory agents on a Friday, with oral 2mg estradiol valerate twice a day from the 2nd day of cycle until the first Friday to follow.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Long luteal GnRH agonist protocol.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol.
Number of subjects: 51

Group type: COMPARATOR
Intervention: GnRH agonist protocol.
Number of subjects: 51
Study: 23683980

Group type: EXPERIMENTAL
Intervention: Positive Action program
Number of subjects: 0
Study: 21267037

Group type: EXPERIMENTAL
Intervention: SCS at subthreshold intensity (SCS80)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: SCS at threshold intensity (SCS100)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (control, no SCS)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: SCS (both SCS80 and SCS100)
Number of subjects: 15
Study: 19470941

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 150 mg/m(2) weekly
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 100 mg/m(2) weekly
Number of subjects: 302

Group type: COMPARATOR
Intervention: nab-paclitaxel q3w
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: All nab-paclitaxel arms
Number of subjects: 302
Study: 16950969

Group type: EXPERIMENTAL
Intervention: Special intervention (brief pediatric provider‐delivered intervention plus peer counseling)
Number of subjects: 2710

Group type: COMPARATOR
Intervention: Usual care condition
Number of subjects: 2710
Study: 15315622

Group type: EXPERIMENTAL
Intervention: A‐line ARX index (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bispectral index (n = 50)
Number of subjects: 100
Study: 11333992

Group type: EXPERIMENTAL
Intervention: Carvedilol (6.25 to 50 mg twice daily)
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1094
Study: 9284847

Group type: EXPERIMENTAL
Intervention: Pindolol with 1.5 gm ammonium chloride (NH4Cl) four times daily for 3 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pindolol with 200 mg trimethoprim once daily for 3 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (pindolol alone)
Number of subjects: 15
Study: 7904188

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate with aspirin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3554082

Group type: EXPERIMENTAL
Intervention: Supplementation with 25,000 IU of retinol daily for up to 3 months
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Supplementation with 50,000 IU of retinol daily for up to 3 months
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no retinol supplementation)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Discontinuation of retinol supplementation
Number of subjects: 46
Study: 29561524

Group type: EXPERIMENTAL
Intervention: 5-s/projection SPECT
Number of subjects: 30

Group type: COMPARATOR
Intervention: Native SPECT
Number of subjects: 30
Study: 26707831

Group type: EXPERIMENTAL
Intervention: Micro-randomized trial design for mobile interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HeartSteps mobile application
Number of subjects: 0
Study: 24156287

Group type: EXPERIMENTAL
Intervention: Lead-in statement suggesting high likelihood of hypertension
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Lead-in statement suggesting normality
Number of subjects: 162
Study: 22615758

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (experienced meditators)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eight meeting mindfulness program (non-meditators)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list group (control)
Number of subjects: 0
Study: 20386259

Group type: EXPERIMENTAL
Intervention: Dynamic deconstructive psychotherapy (DDP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Optimized community care (OCC)
Number of subjects: 30
Study: 18476999

Group type: EXPERIMENTAL
Intervention: Test Brush group with a template slow‐delivery system of chlorhexidine (Ttb)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control Brush group without CHX (Ctb)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control Brush group without CHX but rinsing post‐brushing with a 0.2% CHX mouthrinse (Ctb+R)
Number of subjects: 150
Study: 15922816

Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate (BT) nasal spray 1 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate (BT) nasal spray 2 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12524381

Group type: EXPERIMENTAL
Intervention: Creatine (Cr)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Creatine plus Protein (Cr+P)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 33
Study: 12820740

Group type: EXPERIMENTAL
Intervention: HeartMate vented electric LVAD implantation
Number of subjects: 129

Group type: COMPARATOR
Intervention: Optimal medical management
Number of subjects: 129
Study: 7883742

Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electroshock therapy
Number of subjects: 0
Study: 2568348

Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg and 200 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: D-amphetamine (10 mg and 20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: D-amphetamine (20 mg)
Number of subjects: 10
Study: 1053467

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 50

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 50
Study: 29770722

Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% spray
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate 0.1% cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 0.1% ointment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluocinonide 0.05% gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate 0.1% lotion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% foam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluocinonide 0.05% solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall vehicle characteristics
Number of subjects: 0
Study: 31127666

Group type: EXPERIMENTAL
Intervention: Reprieve therapy (with normal saline for matched volume replacement)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard diuretic therapy
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Reprieve therapy
Number of subjects: 19
Study: 28581401

Group type: EXPERIMENTAL
Intervention: Hippocampal-sparing prophylactic cranial irradiation (PCI) 25 Gy/10 fractions, with a mean hippocampal dose limited to <8 Gy.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hippocampal-sparing prophylactic cranial irradiation (PCI)
Number of subjects: 20
Study: 25832297

Group type: EXPERIMENTAL
Intervention: Nalmefene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23570586

Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) at 200 or 150 mg×m(‐2)d(‐1) for 5 days, repeated every 28 days
Number of subjects: 151

Group type: COMPARATOR
Intervention: Semustine (Me‐CCNU) at 150 mg×m(‐2)×d(‐1) once, repeated every 28 days
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Semustine (Me‐CCNU)
Number of subjects: 151
Study: 21677099

Group type: EXPERIMENTAL
Intervention: Molar bands (cemented with conventional glass ionomer cement)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Molar bonds (bonded with light-cured composite)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Molar bonds
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Molar bands and Molar bonds
Number of subjects: 80
Study: 19201610

Group type: EXPERIMENTAL
Intervention: Dual-task training with variable-priority (VP) instruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-task (ST) balance training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual-task training with fixed-priority (FP) instruction
Number of subjects: 0
Study: 16516059

Group type: EXPERIMENTAL
Intervention: IMPACT protocol (poststudy)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Usual care (historical control)
Number of subjects: 297
Study: 15517847

Group type: EXPERIMENTAL
Intervention: Intramuscular ziprasidone
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Intramuscular haloperidol
Number of subjects: 1005
Study: 10962706

Group type: EXPERIMENTAL
Intervention: Walking program
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Stretching/toning program
Number of subjects: 174
Study: 9068154

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 79
Study: 8473426

Group type: EXPERIMENTAL
Intervention: PCO patients
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 76
Study: 29656132

Group type: EXPERIMENTAL
Intervention: 3D vision system
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4K vision system
Number of subjects: 24

Group type: COMPARATOR
Intervention: 2D vision system
Number of subjects: 24
Study: 26923430

Group type: EXPERIMENTAL
Intervention: S-ROM group (cementless modular stem prostheses)
Number of subjects: 65

Group type: COMPARATOR
Intervention: SLR-PLUS group (cementless coated long-stem prostheses)
Number of subjects: 65
Study: 25474278

Group type: EXPERIMENTAL
Intervention: Oxaliplatin and fluoropyrimidine-based chemotherapy
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: p53 overexpression
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: 2nd and/or 3rd line chemotherapy with irinotecan and/or cetuximab
Number of subjects: 229
Study: 22508711

Group type: EXPERIMENTAL
Intervention: Candesartan (32 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Insulin infusion (1 mU/min · kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Candesartan (32 mg) + Insulin infusion
Number of subjects: 8
Study: 21547174

Group type: EXPERIMENTAL
Intervention: Palonosetron 75 μg intravenously as a bolus before induction of anaesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Granisetron 2.5 mg intravenously as a bolus before induction of anaesthesia
Number of subjects: 60
Study: 18717091

Group type: EXPERIMENTAL
Intervention: 1-stage putty-wash impression
Number of subjects: 48

Group type: COMPARATOR
Intervention: 2-stage putty-wash impression
Number of subjects: 48

Group type: COMPARATOR
Intervention: Monophase impression
Number of subjects: 48
Study: 15745911

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide mouthwash
Number of subjects: 20

Group type: COMPARATOR
Intervention: Commercially available triamcinolone acetonide paste
Number of subjects: 20
Study: 12810240

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg tid
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 10026460

Group type: EXPERIMENTAL
Intervention: ICPP patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ACPP patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Controls (infertile without pain)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ICPP and ACPP patients
Number of subjects: 40
Study: 8739573

Group type: EXPERIMENTAL
Intervention: Variable exercise protocol (GP1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Constant exercise protocols (Gps2-4)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 50% of maximum exercise intensity
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RPE-HR correlation
Number of subjects: 24
Study: 1806619

Group type: EXPERIMENTAL
Intervention: Clozapine, 150-250 mg p.d.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Haloperidol, 20-40 mg p.d.
Number of subjects: 26
Study: 6412376

Group type: EXPERIMENTAL
Intervention: Amino acid solution (group A)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Dextrose‐electrolyte‐calcium solution (group B)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study: 30866088

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Metformin 1500 mg
Number of subjects: 39
Study: 28645636

Group type: EXPERIMENTAL
Intervention: Theobromine (500 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 27339865

Group type: EXPERIMENTAL
Intervention: Activity program delivered by occupational therapists (8 in-home sessions over 3 months)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group intervention delivered by health educators (8 in-home sessions)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Activity program
Number of subjects: 250
Study: 25262372

Group type: EXPERIMENTAL
Intervention: U@Uni intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: U@Uni roll-out to another university
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full implementation of U@Uni
Number of subjects: 0
Study: 22723325

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg once daily
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 205
Study: 21312292

Group type: EXPERIMENTAL
Intervention: Reboxetine 8 mg/day (twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17453688

Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leuprolide 3.75 mg
Number of subjects: 0
Study: 15797959

Group type: COMPARATOR
Intervention: Calcium (1000 mg daily), Vitamin D (800 IU daily), and sex steroid replacement therapy (estrogen for females, testosterone for males)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Calcium (1000 mg daily), Vitamin D (800 IU daily), sex steroid replacement therapy (estrogen for females, testosterone for males), and six iv infusions of pamidronate (60 mg each)
Number of subjects: 99
Study: 11965557

Group type: EXPERIMENTAL
Intervention: External trunk support
Number of subjects: 10

Group type: COMPARATOR
Intervention: No external trunk support
Number of subjects: 10
Study: 9616311

Group type: EXPERIMENTAL
Intervention: Functional dyspepsia patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gastrectomy patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 20
Study: 8745456

Group type: EXPERIMENTAL
Intervention: Combined therapy (radiotherapy + surgery) in 46 patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgery alone in 56 patients
Number of subjects: 100
Study: 2565582

Group type: EXPERIMENTAL
Intervention: Buspirone (acute: 15 mg; subchronic: 5 mg t.i.d.; Day 7: 5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bromazepam (acute: 6 mg; subchronic: 2 mg t.i.d.; Day 7: 2 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12